CN119403828B - 能够与冠状病毒sars-cov-2的刺突蛋白结合的抗体 - Google Patents

能够与冠状病毒sars-cov-2的刺突蛋白结合的抗体

Info

Publication number
CN119403828B
CN119403828B CN202380034355.XA CN202380034355A CN119403828B CN 119403828 B CN119403828 B CN 119403828B CN 202380034355 A CN202380034355 A CN 202380034355A CN 119403828 B CN119403828 B CN 119403828B
Authority
CN
China
Prior art keywords
antibody
antibodies
omicron
omi
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202380034355.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN119403828A (zh
Inventor
J·蒙库尔萨帕亚
G·斯克里顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ruiqiao Biological Covid 19 Co ltd
Original Assignee
Ruiqiao Biological Covid 19 Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2202232.1A external-priority patent/GB202202232D0/en
Priority claimed from GBGB2203423.5A external-priority patent/GB202203423D0/en
Priority claimed from GBGB2212470.5A external-priority patent/GB202212470D0/en
Priority claimed from GBGB2214036.2A external-priority patent/GB202214036D0/en
Priority claimed from GBGB2215418.1A external-priority patent/GB202215418D0/en
Priority claimed from GBGB2301959.9A external-priority patent/GB202301959D0/en
Application filed by Ruiqiao Biological Covid 19 Co ltd filed Critical Ruiqiao Biological Covid 19 Co ltd
Priority claimed from PCT/EP2023/054109 external-priority patent/WO2023156636A1/en
Publication of CN119403828A publication Critical patent/CN119403828A/zh
Publication of CN119403828B publication Critical patent/CN119403828B/zh
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380034355.XA 2022-02-18 2023-02-17 能够与冠状病毒sars-cov-2的刺突蛋白结合的抗体 Active CN119403828B (zh)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
GB2202232.1 2022-02-18
GBGB2202232.1A GB202202232D0 (en) 2022-02-18 2022-02-18 Antibodies
GB2203423.5 2022-03-11
GBGB2203423.5A GB202203423D0 (en) 2022-03-11 2022-03-11 Antibodies
GB2206777.1 2022-05-09
GB202206777 2022-05-09
GB2212470.5 2022-08-26
GBGB2212470.5A GB202212470D0 (en) 2022-08-26 2022-08-26 Antibodies
GB2214036.2 2022-09-26
GBGB2214036.2A GB202214036D0 (en) 2022-09-26 2022-09-26 Antibodies
GB2215418.1 2022-10-18
GBGB2215418.1A GB202215418D0 (en) 2022-10-18 2022-10-18 Antibodies
GBGB2301959.9A GB202301959D0 (en) 2023-02-10 2023-02-10 Antibodies
GB2301959.9 2023-02-10
PCT/EP2023/054109 WO2023156636A1 (en) 2022-02-18 2023-02-17 Antibodies capable of binding to the spike protein of coronavirus sars-cov-2

Publications (2)

Publication Number Publication Date
CN119403828A CN119403828A (zh) 2025-02-07
CN119403828B true CN119403828B (zh) 2025-12-26

Family

ID=86497315

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380034355.XA Active CN119403828B (zh) 2022-02-18 2023-02-17 能够与冠状病毒sars-cov-2的刺突蛋白结合的抗体

Country Status (12)

Country Link
US (1) US20250154231A1 (https=)
EP (1) EP4479425A1 (https=)
JP (1) JP2025507595A (https=)
KR (1) KR20240142594A (https=)
CN (1) CN119403828B (https=)
AU (1) AU2023220851A1 (https=)
CA (1) CA3252608A1 (https=)
CO (1) CO2024012622A2 (https=)
CR (1) CR20240389A (https=)
GB (1) GB2614651B (https=)
IL (1) IL315020A (https=)
MX (1) MX2024010178A (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250289871A1 (en) 2022-04-29 2025-09-18 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
GB202316016D0 (en) * 2023-10-19 2023-12-06 Univ Oxford Innovation Ltd Antibodies
CN121471347B (zh) * 2026-01-12 2026-03-27 中国人民解放军军事科学院军事医学研究院 一种抗SARS-CoV和SARS-CoV-2的全人源单克隆抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021231237A2 (en) * 2020-05-11 2021-11-18 Augmenta Bioworks, Inc. Antibodies for sars-cov-2 and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250107297A (ko) * 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
MX2021015024A (es) * 2020-04-28 2022-01-18 Univ Rockefeller Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
WO2021229561A1 (en) * 2020-05-14 2021-11-18 The Israel Institute of Biological Research (IIBR) Anti-sars-cov-2 antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021231237A2 (en) * 2020-05-11 2021-11-18 Augmenta Bioworks, Inc. Antibodies for sars-cov-2 and uses thereof

Also Published As

Publication number Publication date
KR20240142594A (ko) 2024-09-30
CO2024012622A2 (es) 2024-12-30
MX2024010178A (es) 2024-12-06
GB2614651A (en) 2023-07-12
CR20240389A (es) 2025-05-05
CA3252608A1 (en) 2023-08-24
GB2614651B (en) 2024-03-06
US20250154231A1 (en) 2025-05-15
IL315020A (en) 2024-10-01
AU2023220851A1 (en) 2024-09-26
EP4479425A1 (en) 2024-12-25
JP2025507595A (ja) 2025-03-21
GB202305426D0 (en) 2023-05-31
CN119403828A (zh) 2025-02-07

Similar Documents

Publication Publication Date Title
CN119403828B (zh) 能够与冠状病毒sars-cov-2的刺突蛋白结合的抗体
CN112920269B (zh) 广泛中和性抗hiv抗体
US20240043507A1 (en) Antibodies
WO2021222935A2 (en) Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
EP4230650B1 (en) Antibodies capable of binding to the spike protein of coronavirus sars-cov-2
EP2986637A1 (en) Human antibodies binding to rsv g protein
CN110088131B (zh) 抗chikv抗体及其用途
JP2024506315A (ja) コロナウイルスのスパイクタンパク質を標的とする抗体
AU2023219176A1 (en) Human monoclonal antibodies that broadly target coronaviruses
WO2018022786A1 (en) Antibodies to zika virus and methods of use thereof
US12559544B2 (en) Antibodies that bind human metapneumovirus fusion protein and their use
US20240101645A1 (en) Monoclonal antibodies against coronaviruses and uses thereof
Abu-Shmais et al. A potently neutralizing and protective human antibody targeting antigenic site V on RSV and hMPV fusion glycoprotein
CN114181301B (zh) 针对SARS-CoV-2的无ADE效应的中和抗体
HK40098138A (en) Antibodies capable of binding to the spike protein of coronavirus sars-cov-2
HK40098138B (en) Antibodies capable of binding to the spike protein of coronavirus sars-cov-2
US20250382354A1 (en) Cross-specific antibodies, uses and methods for discovery thereof
WO2025083216A1 (en) Antibodies specific for the spike protein of sars cov-2 coronavirus
CN117337301A (zh) 抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant